363 related articles for article (PubMed ID: 30698208)
1. Apomorphine in the treatment of Parkinson's disease: a review.
Pessoa RR; Moro A; Munhoz RP; Teive HAG; Lees AJ
Arq Neuropsiquiatr; 2018 Dec; 76(12):840-848. PubMed ID: 30698208
[TBL] [Abstract][Full Text] [Related]
2. On demand therapy for Parkinson's disease patients: Opportunities and choices.
Hauser RA; LeWitt PA; Comella CL
Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
[TBL] [Abstract][Full Text] [Related]
3. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Mundt-Petersen U; Odin P
Int Rev Neurobiol; 2017; 134():1019-1044. PubMed ID: 28805563
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
5. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
[TBL] [Abstract][Full Text] [Related]
6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
7. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
Wenzel K; Homann CN; Fabbrini G; Colosimo C
Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
Ludin HP; Surber Ch
Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589
[TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
11. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
12. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
Aschermann Z; Kovács N; Komoly S
Ideggyogy Sz; 2013 May; 66(5-6):209-10. PubMed ID: 23909024
[No Abstract] [Full Text] [Related]
13. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
[TBL] [Abstract][Full Text] [Related]
14. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
15. [Apomorphine in advanced Parkinson disease].
Bogucki A
Neurol Neurochir Pol; 2013; 47(5):476-83. PubMed ID: 24166569
[TBL] [Abstract][Full Text] [Related]
16. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
17. Carbidopa levodopa enteral suspension.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2015; 16(18):2807-17. PubMed ID: 26595228
[TBL] [Abstract][Full Text] [Related]
18. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
van Laar T; Borgemeester R
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S22-S27. PubMed ID: 27998652
[TBL] [Abstract][Full Text] [Related]
19. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
Henriksen T
Neurodegener Dis Manag; 2014; 4(3):271-82. PubMed ID: 25095821
[TBL] [Abstract][Full Text] [Related]
20. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
